A5020258318- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Retinal Imaging and Analysis
- Glaucoma and retinal disorders
- Coronary Interventions and Diagnostics
- Ocular Diseases and Behçet’s Syndrome
- Retinal and Macular Surgery
- Retinal Development and Disorders
- Antiplatelet Therapy and Cardiovascular Diseases
- Intraocular Surgery and Lenses
- Angiogenesis and VEGF in Cancer
- Peripheral Artery Disease Management
- Ophthalmology and Visual Impairment Studies
- Acute Myocardial Infarction Research
- Corneal surgery and disorders
- Cerebrovascular and Carotid Artery Diseases
- Ophthalmology and Eye Disorders
- Facial Trauma and Fracture Management
- Advanced Optical Imaging Technologies
- Anorectal Disease Treatments and Outcomes
- Retinoids in leukemia and cellular processes
- Polymer Surface Interaction Studies
- IgG4-Related and Inflammatory Diseases
- Intramuscular injections and effects
- Long-Term Effects of COVID-19
University of Arizona
2023-2025
Macula and Retina Institute
2024-2025
Retina Macula Institute
2024-2025
Retinal Consultants of Arizona
2015-2024
Lithuanian University of Health Sciences
2024
University of Phoenix
2024
Insight (China)
2024
Celavie Biosciences (United States)
2013-2022
Harlem Hospital Center
2020
St. George's University
2020
Investigate real-world patients receiving faricimab for the treatment of neovascular age-related macular degeneration (nAMD).
Normal human retinal development involves orderly generation of rods and cones by complex mechanisms. Cell-fate specification progenitor cell lineage external signals such as soluble factors cell–cell interactions. In most inherited degenerations, including retinitis pigmentosa, a mutant gene causes loss visual function, death mature rods, eventually all cone subtypes. Only one disorder, the enhanced S syndrome (ESCS), shows increased involving minority (blue) cones, decreased rod L/M...
Purpose: Faricimab, the first bispecific antibody designed for intraocular use, is approved treatment of neovascular age-related macular degeneration (nAMD), diabetic edema (DME), and retinal vein occlusion (RVO). Here, we report usability a novel faricimab 6 mg pre-filled syringe (PFS) configuration that has been specifically intravitreal use. Patients Methods: A simulated-use human factors validation study enrolling 15 retina specialists ophthalmic assistants was conducted in market...
This study evaluated the potential safety, efficacy, and durability advantages of investigational triamcinolone acetonide suspension (CLS-TA; Clearside Biomedical, Alpharetta, GA) administered suprachoroidally in conjunction with intravitreal aflibercept compared monotherapy for treatment diabetic macular edema (DME).TYBEE was a prospective, controlled, double-masked study. Patients were randomized 1:1 to CLS-TA (active) or (control), assessed over 24 weeks.Treatment-naive DME patients...
<h3>Importance</h3> The American Academy of Ophthalmology (AAO) indicated that urgent or emergent vitreoretinal surgical procedures should continue during the coronavirus disease 2019 (COVID-19) pandemic. Although decreases in frequency critical have been reported outside field ophthalmology, analyses are limited by volume, geography, and time. <h3>Objective</h3> To evaluate whether ophthalmic deemed AAO changed across United States COVID-19 <h3>Design, Setting, Participants</h3>...
Purpose To assess the extended efficacy and safety of suprachoroidal triamcinolone acetonide injectable suspension (CLS-TA) among patients with macular oedema (ME) secondary to non-infectious uveitis (NIU). Methods Patients uveitic ME were treated CLS-TA at baseline week 12 Efficacy Safety Suprachoroidal for Macular Edema Secondary Noninfectious Uveitis: Phase 3 Randomized Trial (PEACHTREE) study. Time rescue was evaluated over 24 additional weeks MAGNOLIA. data, visual acuity retinal...
Purpose To evaluate local and systemic safety of suprachoroidal (SC) triamcinolone acetonide injectable suspension (CLS-TA) injections in subjects with non-infectious uveitis (NIU). Design Open-label, prospective multicentre study. Participants Thirty-eight NIU, without macular oedema (MO). Methods Treatment consisted two CLS-TA 4 mg, 12 weeks apart. Best-corrected visual acuity (BCVA), adverse event (AE) assessment, ophthalmic examinations optical coherence tomography (OCT) were conducted...
In VISTA/VIVID, although eyes with better baseline BCVA had lower visual gains at Week 100, they were more likely to achieve ≥ 70 letters and higher VFQ-25 scores than those worse BCVA.
In September 2024, AMCP and Impact Education, LLC, held a virtual Market Insights summit with chief medical pharmacy officers other senior health care executives to discuss the management of retinal diseases in patients diabetes. The aimed explore impact current policies on treatment access costs, identify best practices for anti-vascular endothelial growth factor (anti-VEGF) coverage, address barriers related social determinants (SDOH). Anti-VEGF therapy, although effective conditions such...
The MIRACLE I pilot study was designed as a preliminary investigation of safety and efficacy Embozene TANDEM microspheres loaded with doxorubicin for treatment locally untreatable (i.e., unresectable not suitable local thermal ablation) hepatocellular carcinoma (HCC). Patients HCC (mono- or bilobar disease, ECOG performance status 0–2, Child–Pugh score < 11) were eligible this single-arm multicenter study. DEB-TACE performed 75 µm 150 mg doxorubicin. Twenty-five subjects 41 tumors treated...
This study evaluated the safety and efficacy of elamipretide in dry age-related macular degeneration (AMD) with noncentral geographic atrophy (GA).
Purpose: This study assessed physician-investigator experience with suprachoroidal (SC) injections, an investigational therapeutic administration technique using a 900 or 1100 µm microneedle to inject drugs into the SC space. Methods: Datasets from six clinical trials across three diseases (noninfectious uveitis; diabetic macula edema, and retinal vein occlusion) were assessed. In addition user survey, retrospective correlations performed between procedural variables (needle length),...
Despite the effectiveness of existing anti-vascular endothelial growth factor (VEGF) therapies, a need remains for further treatment options to improve response rates and/or reduce injection or monitoring frequency in patients with diabetic macular edema (DME).To evaluate efficacy and safety brolucizumab vs aflibercept dosed every 4 weeks participants DME.This 52-week, double-masked, phase 3 randomized clinical trial included treatment-naive adults who had previously received anti-VEGF...
This manuscript is a review of the preclinical and early clinical findings related to unique fluorinated polyphosphazene nanolayer device surface modification. Polyzene-F (PzF) novel, high-molecular weight, highly pure that was designed enhance biologic interface between medical human tissue or blood. The polymer also has mechanical properties for first time allow implants be paved with coating nanoscale thickness < 50 nm. inherent thrombus resistant takes on biomimetic soon after implant...
To explore the efficacy of CLS-TA, a proprietary suprachoroidal injectable suspension triamcinolone acetonide, in noninfectious uveitis (NIU) with macular edema (ME), categorized by anatomic subtype.